Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. (Q54359599)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Radical nephrectomy

1 reference

based on heuristic

inferred from title

11

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

object named as

Aidan P Noon

1

0 references

author name string

Radosław Polański

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Ashraf Y El-Fert

3

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Helen Kalirai

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Howida Shawki

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Fiona Campbell

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Andy Dodson

7

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Richard M Eccles

8

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Bryony H Lloyd

9

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

David R Sibson

10

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Sarah L Lake

12

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Keith Parsons

13

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Nikolina Vlatković

14

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Mark T Boyd

15

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

publication date

14 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

109

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

8

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

1250-1257

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

2004 WHO classification of the renal tumors of the adults

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Targeted molecular therapy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

p53 regulation and function in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

The p53-mdm-2 autoregulatory feedback loop

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Using protein expressions to predict survival in clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10433.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2011.10433.X

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21756282

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54359599&oldid=1603808773"